| Literature DB >> 28474543 |
Nady Braidy1, Sahar Behzad2, Solomon Habtemariam3, Touqeer Ahmed4, Maria Daglia5, Seyed Mohammad Nabavi6, Eduardo Sobarzo-Sanchez7, Seyed Fazel Nabavi6.
Abstract
Neurodegenerative diseases, namely Alzheimer's disease and Parkinson's disease represent a deleterious impact worldwide. Despite extensive preclinical and clinical research in neurodegenerative disorders, therapeutic strategies aimed at the prevention and chronic treatment of neurodegenerative conditions have not been successfully translated to the clinic. Therefore, the identification of novel pharmacological intervention derived from natural products is warranted. Nobiletin and tangeretin are important citrus flavonoids derived from the peel and other parts of Citrus L. genus, and have been shown to exhibit neuroprotective effects in several in vitro and in vivo studies. Apart from there antioxidant and anti-inflammatory effects, nobiletin and tangeretin have been shown to attenuate cholinergic deficits, reduce the abnormal accumulation of neurotoxic amyloid-beta peptides, reverse N-methyl- D-aspartate (NMDA) receptor hypofunction, ameliorate ischemic injury, inhibit hyperphosphorylation of tau protein, enhance neprilysin levels, modulate several signaling cascades, and protect against 1-methyl-4-phenylpyridinium (MPP(+)) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity. Taken together, these naturally occurring phytochemicals may represent beneficial drug candidates for the treatment and prevention of Alzheimer's and Parkinson's disease. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Alzheimer's disease; Parkinson’s disease; amyloid; nobiletin; tangeretin; tau
Mesh:
Substances:
Year: 2017 PMID: 28474543 DOI: 10.2174/1871527316666170328113309
Source DB: PubMed Journal: CNS Neurol Disord Drug Targets ISSN: 1871-5273 Impact factor: 4.388